Tirzepatide is already approved to treat type 2 diabetes, and is now approved for chronic weight management in adults with obesity or overweight with at least 1 weight-related condition.
FDA has approved another diabetes drug as a treatment for chronic weight management. Tirzepatide has been approved for weight loss in adults with a body mass index of 27 kg/m2 or greater who also have a weight-related medical condition, such as hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease.
Eli Lilly will market tirzepatide as a weight loss drug under the name Zepbound. Tirzepatide is already approved to treat adults with type 2 diabetes under the name Mounjaro. This is the second diabetes drug that has been approved for a weight loss indication, following the approval of Wegovy (semaglutide; sold as Ozempic to treat type 2 diabetes) in June 2021.
Zepbound was originally approved to treat type 2 diabetes in adults and is now approved for chronic weight management.
Image credit: Africa Studio - stock.adobe.com
"Obesity is a chronic disease that can result in serious health complications, including heart disease, stroke, and diabetes. Despite our knowledge of obesity as a treatable, chronic disease, people living with obesity still face many challenges in their health and weight management journey," Joe Nadglowski, president and CEO of the Obesity Action Coalition, said in a statement.2 "New treatment options bring hope to the many people with obesity who struggle with this disease and are seeking better options for weight management."
Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that is administered once weekly via injection. The approval was based on the phase 3 SURMOUNT-1 and SURMOUNT-2 trials.
SURMOUNT-1 results were published in 2022 in New England Journal of Medicine3 and adults with obesity had average weight reductions of 19.5% on the 10-mg dose and 20.9% on the 15-mg dose by week 72. In comparison, patients on placebo had a weight reduction of 3.1%.
“This is an unusually substantial degree of weight reduction in response to an antiobesity medication as compared with findings reported in other phase 3 clinical trials,” the authors wrote. “Given that tirzepatide is both a GIP receptor and GLP-1 receptor agonist, we speculate that there may be additive benefit in targeting multiple endogenous nutrient-stimulated hormone pathways that have been implicated in energy homeostasis.”
In SURMOUNT-2, which was published June 2023 in The Lancet,4 participants had reductions in mean body weight up to 14.7%. For patients on the 15-mg dose, up to 65% of participants had reductions of 10% or more and 31% had reductions of 20% or more by week 72.
Common adverse events include nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, injection-site reactions, fatigue, hypersensitivity reactions, burping, hair loss, and gastroesophageal reflux disease.
“Unfortunately, despite scientific evidence to the contrary, obesity is often seen as a lifestyle choice—something that people should manage themselves,” said Leonard Glass, MD, senior vice president of global medical affairs, Lilly Diabetes and Obesity.2 “For decades, diet and exercise have been a go-to, but it's not uncommon for a person to have tried 20-30 times to lose weight with this approach. Research now shows that the body may respond to a calorie-deficit diet by increasing hunger and reducing feelings of fullness, making weight loss more difficult.”
Wegovy costs about $1349 a month without insurance,5 and most private insurance companies and the federal health programs do not cover it.6 With insurance, Ozempic can cost as little as $25 for a monthly supply, but without insurance it can cost approximately $935 per month.7 At its list price of $1059.87, Zepbound will cost approximately 20% less than Wegovy 2.5 mg. Zepbound will be available in 6 doses—2.5, 5, 7.5, 10, 12.5, and 15 mg.
References
1. FDA approves new medication for chronic weight management. News release. News release. FDA. November 8, 2023. Accessed November 8, 2023. https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management
2. FDA approves Lilly's Zepbound (tirzepatide) for chronic weight management, a powerful new option for the treatment of obesity or overweight with weight-related medical problems. News release. Lilly. November 8, 2023. Accessed Novenber 8, 2023. https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-zepboundtm-tirzepatide-chronic-weight
3. Jastreboff AM, Aronee LJ, Ahmad NN, et al; for the SURMOUNT-1 investigators. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038
4. Garvey WT, Frias JP, Jastreboff AM, et al; for the SURMOUNT-2 investigators. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023;402(10402):613-626. doi:10.1016/S0140-6736(23)01200-X
5. What is the list price of Wegovy and will it impact me? NovoCare. Accessed November 8, 2023. https://www.novocare.com/obesity/products/wegovy/let-us-help/explaining-list-price.html
6. Tu L. Should insurance cover Wegovy, Ozempic and other new weight loss drugs? Scientific American. October 16, 2023. Accessed November 8, 2023. https://www.scientificamerican.com/article/should-insurance-cover-wegovy-ozempic-and-other-new-weight-loss-drugs/
7. Find out the cost of Ozempic. NovoCare. Accessed November 8, 2023. https://www.novocare.com/diabetes/products/ozempic/explaining-list-price.html
Study Highlights Key RA-ILD Risk Factors, Urges Early Screening
November 20th 2024This recent study highlights key risk factors for rheumatoid arthritis–associated interstitial lung disease (RA-ILD), emphasizing the importance of early screening to improve diagnosis and patient outcomes.
Read More
Building Trust, Breaking Barriers: Health Care Leaders Tackle Primary Care Challenges
August 8th 2024On this episode of Managed Care Cast, we're talking with the chief medical officers of CVS Health and Aetna, as well as CVS Health's chief health equity officer, about primary and preventive care engagement, the impact of telehealth, and the role of trust in patient-provider relationships.
Listen
OS Better With Belantamab Mafodotin Triplet vs Daratumumab in R/R MM
November 19th 2024The key secondary end point of overall survival (OS) was met in the DREAMM-7 trial of belantamab mafodotin (Blenrep; GSK) for the treatment of patients with relapsed/refractory multiple myeloma (R/R MM).
Read More
